The 2018 American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) consensus showed a paradigm shift from a treat-to-goal approach to a treat-to-benefit approach, which was driven by the results from CVOTs that demonstrated the benefits of SGLT2i and GLP-1 RAs on hypoglycemic risk, CV outcomes and extra-glycemic benefits on weight, and blood pressure [22]. Here, GLP1R is linked to diabetes mellitus.